Source: Benzinga

Calliditas Therapeutics: Why Calliditas Therapeutics Stock Trading Higher Today

Calliditas Therapeutics (NASDAQ: CALT) shares are trading higher on Tuesday after Jefferies initiated coverage on the stock with a Buy rating and a price target of $44 per share.Calliditas Therapeutics operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is ...Full story available on Benzinga.com

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Renee Aguiar-Lucander's photo - CEO of Calliditas

CEO

Renee Aguiar-Lucander

CEO Approval Rating

90/100

Calliditas is a pharmaceutical company that develops and commercializes therapeutics for the treatment of inflammatory kidney diseases. Read more